TopFunds

Solventum

NYSE: SOLV

Stock price

81.43 USD

(+0%) TODAY

Health Care TechnologyMedical - Care Facilities
Financials

all figures in US$ Millions except per share data

Sections:

Periods:

View:

Format:

Actual
10 year cagr
Help
Where available up to 10y CAGR shown for absolute numbers 10y Average marked A shown for relative numbers such as margins
Fiscal
2020
2021
2022
2023
2024
2025
Average (A)
Fiscal period end dates
Expand all rows
01Earnings per share
Help
Earnings per share = Net Income / Number of Shares Outstanding
6.6
8.5
7.8
7.8
2.8
8.9
6.1%
02Free cash flow per share
10.2
11.2
8.3
9.4
4.6
(0.1)
-
03Dividends per share
-
-
-
-
-
-
-
04Dividends payout, %
-
-
-
-
-
-
-
PROFIT AND LOSS STATEMENT
05Revenue
$ 7,281
$ 8,171
$ 8,130
$ 8,197
$ 8,254
$ 8,325
2.7%
06% Change
-
12.2%
(0.5)%
0.8%
0.7%
0.9%
2.7%
07Cost of revenue
(2,966)
(3,248)
(3,435)
(3,504)
(3,661)
(3,874)
5.5%
08Gross profit
4,315
4,923
4,695
4,693
4,593
4,451
0.6%
09% Margin
59.3%
60.3%
57.8%
57.3%
55.7%
53.5%
57.3% A
10Operating expenses
(2,885)
(3,044)
(3,002)
(3,001)
(3,557)
(2,270)
(4.7)%
11% of Revenue
(39.6)%
(37.3)%
(36.9)%
(36.6)%
(43.1)%
(27.3)%
(36.8)% A
12Operating Income
1,430
1,879
1,693
1,692
1,036
2,181
8.8%
13Income tax expense
(302)
(422)
(349)
(321)
(127)
(157)
(12.3)%
14Net Income
1,138
1,460
1,343
1,346
479
1,556
6.5%
15% Margin
15.6%
17.9%
16.5%
16.4%
5.8%
18.7%
15.2% A
16Shares Outstanding
172,466
172,466
172,466
172,710
173,700
175,300
0.3%
17EPS Basic
6.6
8.5
7.8
7.8
2.8
8.9
6.3%
18EPS Diluted
6.6
8.5
7.8
7.8
2.8
8.9
6.1%
19EBITDA
2,029
2,479
2,270
2,228
1,527
2,549
4.7%
% Margin
27.9%
30.3%
27.9%
27.2%
18.5%
30.6%
27.1% A
20Net Interest Income (expense)
-
-
-
-
(367)
(347)
-
21Net Debt / EBITDA
-
-
-
3.6
4.7
1.6
2 A
BALANCE SHEET
ASSETS
Current Assets
22Cash & equivalents
-
91
61
194
762
878
76.2%
23Short-term investments
-
-
-
-
-
-
-
24Accounts receivable
-
1,177
1,171
1,313
1,229
1,034
(3.2)%
25Other current assets
-
108
126
155
293
881
69%
26Inventory
-
813
873
857
965
1,066
7%
27Total Current Assets
-
2,189
2,231
2,519
3,249
3,859
15.2%
Non-Current Assets
28Net property, plant & equipment
-
1,306
1,319
1,457
1,622
1,326
0.4%
29Long-term investments
-
-
-
-
-
-
-
30Other non-current assets
-
10,580
10,044
9,967
9,586
9,109
(3.7)%
31Total Non-Current Assets
-
11,886
11,363
11,424
11,208
10,435
(3.2)%
Total Assets
-
14,075
13,594
13,943
14,457
14,294
0.4%
LIABILITIES
Current Liabilities
32Accounts payable
-
320
348
477
618
687
21.1%
33Short-term debt
-
29
27
-
200
-
-
34Other current liabilities
-
1,057
936
1,251
1,885
2,449
23.4%
35Total Current Liabilities
-
1,406
1,311
1,728
2,703
3,136
22.2%
Non-Current Liabilities
36Long-term debt
-
83
68
8,303
7,810
5,035
179.1%
37Other non-current liabilities
-
527
473
(7,754)
985
1,074
19.5%
38Total Non-Current Liabilities
-
610
541
549
8,795
6,109
77.9%
39Total Liabilities
-
2,016
1,852
2,277
11,498
9,245
46.3%
SHAREHOLDERS` EQUITY
40Common stock
-
-
-
-
2
2
-
41Retained earnings / (deficit)
-
-
-
-
242
1,797
-
42Accumulated other comprehensive income / (loss)
-
(200)
(497)
(337)
(1,056)
(625)
33%
43Noncontrolling interests
-
-
-
-
-
-
-
44Total shareholders' equity
-
12,059
11,742
11,666
2,959
5,049
(19.6)%
45Total Liabilities and shareholders' Equity
-
14,075
13,594
13,943
14,457
14,294
0.4%
46Total Debt
-
112
95
8,303
8,010
5,035
158.9%
47Net Debt
-
21
34
8,109
7,248
4,157
275.1%
CASH FLOW STATEMENT
CASH FLOWS FROM OPERATING ACTIVITIES
48Net income (loss)
1,138
1,460
1,343
1,346
479
1,556
6.5%
49Depreciation & amortization
599
597
578
561
555
489
(4)%
50Share-based compensation expense
35
38
37
39
112
161
35.7%
51Changes in working capital and other assets
254
107
(279)
(31)
39
(1,837)
-
52Net cash flows from operating activities
2,026
2,202
1,679
1,915
1,185
369
(28.9)%
CASH FLOWS FROM INVESTING ACTIVITIES
53Purchases of property, plant and equipment
(271)
(277)
(251)
(290)
(380)
(379)
6.9%
54Purchases of investments / marketable securities
-
-
-
-
-
-
-
55Proceeds from maturities of marketable securities
469
-
-
-
-
-
-
56Other investing activities
30
(1)
(2)
60
-
3,176
154.1%
57Net cash flows from investing activities
228
(278)
(253)
(230)
(380)
2,797
65.1%
CASH FLOWS FROM FINANCING ACTIVITIES
58Issuance (repurchases) of common stock, net
-
-
-
-
-
-
-
59Dividends paid, net
-
-
-
-
-
-
-
60Debt issuance (repayments), net
(445)
-
-
-
8,003
(3,070)
47.2%
61Other financing activities
(1,766)
(1,960)
(1,460)
(1,552)
(8,243)
13
-
62Net cash flows from financing activities
(2,211)
(1,960)
(1,460)
(1,552)
(240)
(3,057)
6.7%
63Increase (decrease) in cash and cash equivalents
40
(33)
(30)
133
568
116
23.7%
64Cash and equivalents, ending balance
124
91
61
194
762
878
47.9%
65Free Cash Flow to the Firm (FCFF)
Help
Free Cash Flow to the Firm = Cash Flows from Operating Activities - Capital Expenditures
1,755
1,925
1,428
1,625
805
(10)
-

Annual Reports, Presentations And IR Contacts

Go to the website
Annual report links (10K)
20252024

Solventum (SOLV) financial statements and performance

Explore Solventum (SOLV) annual and quarterly financial statements, including revenue, operating income, net income, cash flow, assets, liabilities, and per-share metrics.

Compare reporting periods and financial trends to evaluate profitability, balance-sheet strength, cash generation, and long-term business performance.